Hypoxia-inducible factors in the kidney

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 2, 2006, Pages

  Haase, Volker H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Erythropoiesis; Renal cell cancer; Renal fibrosis; Renal ischemia reperfusion injury

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE E3; VON HIPPEL LINDAU PROTEIN;

ALPHA CHAIN; ANGIOGENESIS; APOPTOSIS; BETA CHAIN; CELL PROLIFERATION; ENDOTHELIUM CELL; ENERGY METABOLISM; ERYTHROPOIESIS; FIBROBLAST; GENE EXPRESSION; HUMAN; HYDROXYLATION; HYPOXIA; IRON METABOLISM; KIDNEY CANCER; KIDNEY DEVELOPMENT; KIDNEY INJURY; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN SENSING; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 33746655373     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00071.2006     Document Type: Review

References (145)

1. Adelman DM, Gertsenstein M, Nagy A, Simon MC, and Maltepe E. Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses. Genes Dev 14: 3191-3203, 2000.
2. Adelman DM, Maltepe E, and Simon MC. Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev 13: 2478-2483, 1999.
3. Agani FH, Pichiule P, Chavez JC, and LaManna JC. The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia. J Biol Chem 275: 35863-35867, 2000.
4. Agarwal A and Nick HS. Renal response to tissue injury: lessons from heme oxygenase-1 gene ablation and expression. J Am Soc Nephrol 11: 965-973, 2000.
5. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, and Prchal JT. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nature Genet 32: 614-621, 2002.
6. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, and Gleadle JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279: 38458-38465, 2004.
7. Bernhardt WM, Kany S, Campean V, Juergensen JS, Weidemann A, Warnecke C, Klaus S, Guenzler V, Amann K, Willam C, Wiesener M, and Eckardt KU. Preconditional activation of HIF ameliorates ischemic acute renal failure. ASN Annual Meeting, Philadelphia, PA (Abstract). J Am Soc Nephrol 16: 195A, 2005.
8. Bernhardt WM, Schmitt R, Rosenberger C, Munchenhagen PM, Grone HJ, Frei U, Warnecke C, Bachmann S, Wiesener MS, Willam C, and Eckardt KU. Expression of hypoxia-inducible transcription factors in developing human and rat kidneys. Kidney Int 69: 114-122, 2006.
9. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22: 4082-4090, 2003.
10. Biju MP, Akai Y, Shrimanker N, and Haase VH. Protection of HIF-1-deficient primary renal tubular epithelial cells from hypoxia-induced cell death is glucose dependent. Am J Physiol Renal Physiol 289: F1217-F1226, 2005.
11. Bindra RS, Vasselli JR, Stearman R, Linehan WM, and Klausner RD. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62: 3014-3019, 2002.
12. Brukamp K, Jim B, Moeller MJ, Holzman LB, and Haase VH. VHL deficiency in novel podocyte cell lines results in survival disadvantage. ASN Annual Meeting, Philadelphia, PA (Abstract). J Am Soc Nephrol 16: 157A, 2005.
13. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, and Chandel NS. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 1: 409-414, 2005.
14. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, and Semenza GL. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108: 79-85, 2003.
15. Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, Apasov SG, and Sitkovsky MV. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol 167: 6140-6149, 2001.
16. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, and Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95: 11715-11720, 1998.
17. 2 sensing. J Biol Chem 275: 25130-25138, 2000.
18. Chatha RK, Johnson AM, Rothberg PG, Townsend RR, Neumann HP, and Gabow PA. Von Hippel-Lindau disease masquerading as autosomal dominant polycystic kidney disease. Am J Kidney Dis 37: 852-858, 2001.
19. Chavez JC, Baranova O, LanManna JC, and Ratan RR. Brain specific deletion of the HIF-1α gene increases ischemic injury in a mouse model of focal cerebral ischemia (Hypoxia and Development, Physiology and Disease, Breckenridge, CO, Keystone Symposia). Silverthorne, CO: Keystone Symposia on Molecular and Cellular Biology, 2006, p. 67.
20. Compernolle V, Brusselmans K, Acker T, Hoet P, Tjwa M, Beck H, Plaisance S, Dor Y, Keshet E, Lupu F, Nemery B, Dewerchin M, Van Veldhoven P, Plate K, Moons L, Collen D, and Carmeliet P. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 8: 702-710, 2002.
21. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon MC, and Keith B. HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20: 557-570, 2006.
22. Cowden Dahl KD, Fryer BH, Mack FA, Compernolle V, Maltepe E, Adelman DM, Carmeliet P, and Simon MC. Hypoxia-inducible factors 1α and 2α regulate trophoblast differentiation. Mol Cell Biol 25: 10479-10491, 2005.
23. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, and Johnson RS. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112: 645-657, 2003.
24. Ding M, Cui S, Binnie M, Jothy S, Li C, Nagy A, Steer BM, Marsden P, Rastaldi MP, Haase VH, Cohen CD, Kretzler M, and Quaggin SE. Loss of the tumor suppressor VHL leads to rapidly progressive glomerulonephritis and pulmonary hemorrhage in mice. ASN Annual Meeting, Philadelphia, PA (Abstract). J Am Soc Nephrol 16: 107A, 2005.
25. Enomoto N, Koshikawa N, Gassmann M, Hayashi J, and Takenaga K. Hypoxic induction of hypoxia-inducible factor-1α and oxygen-regulated gene expression in mitochondrial DNA-depleted HeLa cells. Biochem Biophys Res Commun 297: 346-352, 2002.
26. 1. J Cell Physiol 191: 42-50, 2002.
27. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 286: R977-R988, 2004.
28. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, and Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res 59: 3915-3918, 1999.
29. Fine LG, Bandyopadhay D, and Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int 57, Suppl 75: S22-S26, 2000.
30. Fleming RE and Bacon BR. Orchestration of iron homeostasis. N Engl J Med 352: 1741-1744, 2005.
31. Freeburg PB, Robert B, St. John PL, and Abrahamson DR. Podocyte expression of hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular development. J Am Soc Nephrol 14: 927-938, 2003.
32. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, and Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211, 2002.
33. Ganz T and Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 290: G199-G203, 2006.
34. Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, and Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 118: 781-794, 2004.
35. Gnarra JR, Ward JM, Porter FD, Wagner JR, Devor DE, Grinberg A, Emmert-Buck MR, Westphal H, Klausner RD, and Linehan WM. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 94: 9102-9107, 1997.
36. Gordeuk VR, Sergueeva AI, Miasnikova GY, Okhotin D, Voloshin Y, Choyke PL, Butman JA, Jedlickova K, Prchal JT, and Polyakova LA. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 103: 3924-3932, 2004.
37. Greijer AE and van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57: 1009-1014, 2004.
38. Guo G, Lin A, Guenzler V, Liu DY, Klaus S, Arend M, Flippin L, Langsetmo I, Witschi C, and Wang QJ. Improvement of kidney function in a rat model of renal ischemia-reperfusion injury by treatment with a novel HIF prolyl-hydroxylase inhibitor. ASN Annual Meeting, St. Louis, MO (Abstract). J Am Soc Nephrol 15: 460A, 2004.
39. Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J, Ruas JL, Poellinger L, Lendahl U, and Bondesson M. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9: 617-628, 2005.
40. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, and Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 1: 401-408, 2005.
41. Haase VH. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Semin Cell Dev Biol 16: 564-574, 2005.
42. Haase VH, Glickman JN, Socolovsky M, and Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 98: 1583-1588, 2001.
43. Hagen T, Taylor CT, Lam F, and Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1α. Science 302: 1975-1978, 2003.
44. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
45. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, and Jelkmann W. Interleukin-1β and tumor necrosis factor-α stimulate DNA binding of hypoxia-inducible factor-1. Blood 94: 1561-1567, 1999.
46. Helton R, Cui J, Scheel JR, Ellison JA, Ames C, Gibson C, Blouw B, Ouyang L, Dragatsis I, Zeitlin S, Johnson RS, Lipton SA, and Barlow C. Brain-specific knock-out of hypoxia-inducible factor-1α reduces rather than increases hypoxic-ischemic damage. J Neurosci 25: 4099-4107, 2005.
47. Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, and Haase VH. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol 287: F1223-F1232, 2004.
48. Higgins DF, Johnson RS, and Haase VH. Hypoxic signaling enhances renal fibrosis (Hypoxia and Development, Physiology and Disease, Breckenridge, CO, Keystone Symposia). Silverthorne, CO: Keystone Symposia on Molecular and Cellular Biology, 2006, p. 74.
49. Horikawa S, Yoneya R, Nagashima Y, Hagiwara K, and Ozasa H. Prior induction of heme oxygenase-1 with glutathione depletor ameliorates the renal ischemia and reperfusion injury in the rat. FEBS Lett 510: 221-224, 2002.
50. Hu CJ, Wang LY, Chodosh LA, Keith B, and Simon MC. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374, 2003.
51. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, and Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8: 143-153, 2005.
52. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev 12: 149-162, 1998.
53. Jelkmann W. Molecular biology of erythropoietin. Intern Med 43: 649-659, 2004.
54. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, and Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 363-369, 2001.
55. 2 tension. Am J Physiol Cell Physiol 271: C1172-C1180, 1996.
56. Kaelin WG. Proline hydroxylation and gene expression. Annu Rev Biochem 74: 115-128, 2005.
57. Kairaitis LK, Wang Y, Gassmann M, Tay YC, and Harris DC. HIF-1α expression follows microvascular loss in advanced murine adriamycin nephrosis. Am J Physiol Renal Physiol 288: F198-F206, 2005.
58. Kalluri R and Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003.
59. Kang DH, Hughes J, Mazzali M, Schreiner GF, and Johnson RJ. Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448-1457, 2001.
60. Kietzmann T, Roth U, and Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 94: 4177-4185, 1999.
61. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, and Johnson RJ. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 58: 2390-2399, 2000.
62. Kimura K, Iwano M, Akai Y, Nakatani K, Harada K, Yamaguchi Y, Saito Y, Johnson RS, Neilson EG, and Haase VH. HIF-1α is a key molecule for the progression of EMT-mediated renal fibrosis. ASN Annual Meeting, Philadelphia, PA (Abstract). J Am Soc Nephrol 16: 656A, 2005.
63. Kojima H, Gu H, Nomura S, Caldwell CC, Kobata T, Carmeliet P, Semenza GL, and Sitkovsky MV. Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1α-deficient chimeric mice. Proc Natl Acad Sci USA 99: 2170-2174, 2002.
64. Kondo K, Kim WY, Lechpammer M, and Kaelin WG Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth (Abstract). PLoS Biol 1: E83, 2003.
65. Kondo K, Klco JM, Nakamura E, Lechpammer M, and Kaelin WG. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246, 2002.
66. Kong T, Eltzschig HK, Karhausen J, Colgan SP, and Shelley CS. Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of β2 integrin gene expression. Proc Natl Acad Sci USA 101: 10440-10445, 2004.
67. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, and Huang LE. HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J 23: 1949-1956, 2004.
68. Kudo Y, Kakinuma Y, Mori Y, Morimoto N, Karashima T, Furihata M, Sato T, Shuin T, and Sugiura T. Hypoxia-inducible factor-1α is involved in the attenuation of experimentally induced rat glomerulonephritis. Nephron Exp Nephrol 100: e95-e103, 2005.
69. Langsetmo I, Nichols B, Seeley T, Stephenson B, Klaus S, Lin A, and Liu DY. FG-2216 corrects anemia and improves iron utilization in a rat model of anemia of chronic disease: comparison to darbepoetin. ASN Annual Meeting, Philadelphia, PA (Abstract). J Am Soc Nephrol 16: 481A, 2005.
70. Laughner E, Taghavi P, Chiles K, Mahon PC, and Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001.
71. Liu DY, Neff TB, Guenzler V, Langsetmo I, Fourney P, Nichols B, Muthukrishnan E, Lin A, and Klaus S. Novel and beneficial pharmacodynamic properties of endogenous EPO and complete erythropoiesis induced by selective HIF prolyl hydroxylase inhibitors. ASN Annual Meeting, Philadelphia, PA (Abstract). J Am Soc Nephrol 16: 761A, 2005.
72. Liu MY, Poellinger L, and Walker CL. Up-regulation of hypoxia-inducible factor 2α in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res 63: 2675-2680, 2003.
73. Lok CN and Ponka P. Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 274: 24147-24152, 1999.
74. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, and Oldfield EH. von Hippel-Lindau disease. Lancet 361: 2059-2067, 2003.
75. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, and Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414: 550-554, 2001.
76. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, and Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386: 403-407, 1997.
77. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, and Maxwell PH. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1: 459-468, 2002.
78. Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, Kurokawa K, Fujita T, Ingelfinger JR, and Nangaku M. Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 65: 871-880, 2004.
79. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, and Simon MC. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-α activation. Cell Metab 1: 393-399, 2005.
80. Maranchi JK, Vasselli JR, Riss J, Bonifacio JS, Linehan WM, and Klausner RD. The contribution of VHL substrate binding and HIF-1α to the phenotype of vhl loss in renal cell carcinoma. Cancer Cell 1: 247-253, 2002.
81. Matsumoto M, Makino Y, Tanaka T, Tanaka H, Ishizaka N, Noiri E, Fujita T, and Nangaku M. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol 14: 1825-1832, 2003.
82. Matsumoto M, Tanaka T, Yamamoto T, Noiri E, Miyata T, Inagi R, Fujita T, and Nangaku M. Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis. J Am Soc Nephrol 15: 1574-1581, 2004.
83. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
84. Morimoto K, Ohta K, Yachie A, Yang Y, Shimizu M, Goto C, Toma T, Kasahara Y, Yokoyama H, Miyata T, Seki H, and Koizumi S. Cytoprotective role of heme oxygenase (HO)-1 in human kidney with various renal diseases. Kidney Int 60: 1858-1866, 2001.
85. Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, Nakajima O, Kawauchi S, Ema M, Shibahara S, Udono T, Tomita K, Tamai M, Sogawa K, Yamamoto M, and Fujii-Kuriyama Y. HLF/HIF-2α is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J 22: 1134-1146, 2003.
86. Morrison SJ, Csete M, Groves AK, Melega W, Wold B, and Anderson DJ. Culture in reduced levels of oxygen promotes clonogenic sympathoadrenal differentiation by isolated neural crest stem cells. J Neurosci 20: 7370-7376, 2000.
87. Neumann AK, Yang J, Biju MP, Joseph SK, Johnson RS, Haase VH, Freedman BD, and Turka LA. Hypoxia inducible factor 1α regulates T cell receptor signal transduction. Proc Natl Acad Sci USA 102: 17071-17076, 2005.
88. Norman JT, Clark IM, and Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 58: 2351-2366, 2000.
89. 1-independent mechanism. Kidney Int 52: 637-647, 1997.
90. Pastore Y, Jedlickova K, Guan Y, Liu E, Fahner J, Hasle H, Prchal JF, and Prchal JT. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am J Hum Genet 73: 412-419, 2003.
91. Peng J, Zhang L, Drysdale L, and Fong GH. The transcription factor EPAS-1/hypoxia-inducible factor 2α plays an important role in vascular remodeling. Proc Natl Acad Sci USA 97: 8386-8391, 2000.
92. Percy MJ, Zhao Q, Flores A, Harrison C, Lappin TR, Maxwell PH, McMullin MF, and Lee FS. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 103: 654-659, 2006.
93. Rankin EB, Higgins DF, Walisser JA, Johnson RS, Bradfield CA, and Haase VH. Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol 25: 3163-3172, 2005.
94. Rankin EB, Keith B, Simon C, and Haase VH. Inactivation of HIF-2α suppresses the VHL associated phenotype in the liver (Hypoxia and Development, Physiology and Disease, Breckenridge, Co. Keystone Symposia). Silverthorne, CO: Keystone Symposia on Molecular and Cellular Biology, 2006, p. 92.
95. Rankin EB, Tomaszewski JE, and Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res 66: 2576-2583, 2006.
96. Ratan RR, Siddiq A, Aminova L, Lange PS, Langley B, Ayoub I, Gensert J, and Chavez J. Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy. Stroke 35: 2687-2689, 2004.
97. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, and Ratcliffe PJ. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-5686, 2005.
98. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 14: 34-44, 2000.
99. Richard DE, Berra E, and Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. J Biol Chem 275: 26765-26771, 2000.
100. Rolfs A, Kvietikova I, Gassmann M, and Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 272: 20055-20062, 1997.
101. Rosenberger C, Griethe W, Gruber G, Wiesener M, Frei U, Bachmann S, and Eckardt KU. Cellular responses to hypoxia after renal segmental infarction. Kidney Int 64: 874-886, 2003.
102. Rosenberger C, Heyman SN, Rosen S, Shina A, Goldfarb M, Griethe W, Frei U, Reinke P, Bachmann S, and Eckardt KU. Up-regulation of HIF in experimental acute renal failure: evidence for a protective transcriptional response to hypoxia. Kidney Int 67: 531-542, 2005.
103. Rosenberger C, Mandriota S, Jurgensen JS, Wiesener MS, Horstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, and Eckardt KU. Expression of hypoxia-inducible factor-1α and -2α in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13: 1721-1732, 2002.
104. Ruas JL and Poellinger L. Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin Cell Dev Biol 16: 514-522, 2005.
105. Ryan HE, Lo J, and Johnson RS. HIF-1 α is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998.
106. Ryan HE, Poloni M, McNulty W, Elson D, Gassmann M, Arbeit JM, and Johnson RS. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 60: 4010-4015, 2000.
107. 1. Wound Repair Regen 7: 504-510, 1999.
108. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, and Bernabeu C. Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. J Biol Chem 276: 38527-38535, 2001.
109. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, and Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-β pathways. J Biol Chem 277: 43799-43808, 2002.
110. Sanchez-Elsner T, Ramirez JR, Sanz-Rodriguez F, Varela E, Bernabeu C, and Botella LM. A cross-talk between hypoxia and TGF-β orchestrates erythropoietin gene regulation through SP1 and Smads. J Mol Biol 336: 9-24, 2004.
111. Sandau KB, Zhou J, Kietzmann T, and Brune B. Regulation of the hypoxia-inducible factor 1α by the inflammatory mediators nitric oxide and tumor necrosis factor-α in contrast to desferroxamine and phenylarsine oxide. J Biol Chem 276: 39805-39811, 2001.
112. Schofield CJ and Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354, 2004.
113. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan LJ, Marck BT, Matsumoto AM, Shelton JM, Richardson JA, Bennett MJ, and Garcia JA. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat Genet 35: 331-340, 2003.
114. Scortegagna M, Ding K, Zhang Q, Oktay Y, Bennett MJ, Bennett M, Shelton JM, Richardson JA, Moe O, and Garcia JA. HIF-2α regulates murine hematopoietic development in an erythropoietin-dependent manner. Blood 105: 3133-3140, 2005.
115. Sitkovsky M and Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1α and adenosine receptors. Nat Rev Immunol 5: 712-721, 2005.
116. Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, and Lee S. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res 65: 5221-5230, 2005.
117. Soilleux EJ, Turley H, Tian YM, Pugh CW, Gatter KC, and Harris AL. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology 47: 602-610, 2005.
118. Srinivas V, Leshchinsky I, Sang N, King MP, Minchenko A, and Caro J. Oxygen sensing and HIF-1 activation does not require an active mitochondrial respiratory chain electron-transfer pathway. J Biol Chem 276: 21995-21998, 2001.
119. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, and Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425: 307-311, 2003.
120. Steenhard B, Isom K, Stroganova L, St John PL, Freeburg PB, Holzman LB, and Abrahamson DR. Podocyte-selective deletion of von Hippel-Lindau (VHL) protein causes albuminuria. ASN Annual Meeting, Philadelphia, PA (Abstract). J Am Soc Nephrol 16: 667A, 2005.
121. Stiehl DP, Jelkmann W, Wenger RH, and Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor 1α by insulin and interleukin-1β involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 512: 157-162, 2002.
122. Stolze IP, Tian YM, Appelhoff RJ, Turley H, Wykoff CC, Gleadle JM, and Ratcliffe PJ. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. J Biol Chem 279: 42719-42725, 2004.
123. Studer L, Csete M, Lee SH, Kabbani N, Walikonis J, Wold B, and McKay R. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci 20: 7377-7383, 2000.
124. Tacchini L, Bianchi L, Bernelli-Zazzera A, and Cairo G. Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 274: 24142-24146, 1999.
125. Tanaka T, Kojima I, Ohse T, Inagi R, Miyata T, Ingelfinger JR, Fujita T, and Nangaku M. Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. Am J Physiol Renal Physiol 289: F1123-F1133, 2005.
126. Tanaka T, Kojima I, Ohse T, Ingelfinger JR, Adler S, Fujita T, and Nangaku M. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest 85: 1292-1307, 2005.
127. Tanaka T, Matsumoto M, Inagi R, Miyata T, Kojima I, Ohse T, Fujita T, and Nangaku M. Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int 68: 2714-2725, 2005.
128. Tian H, Hammer RE, Matsumoto AM, Russell DW, and McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev 12: 3320-3324, 1998.
129. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, and Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277: 27975-27981, 2002.
130. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, and Harris AL. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62: 2957-2961, 2002.
131. Vaux EC, Metzen E, Yeates KM, and Ratcliffe PJ. Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood 98: 296-302, 2001.
132. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, and Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19: 348-355, 2004.
133. Vogt BA, Shanley TP, Croatt A, Alam J, Johnson KJ, and Nath KA. Glomerular inflammation induces resistance to tubular injury in the rat. A novel form of acquired, heme oxygenase-dependent resistance to renal injury. J Clin Invest 98: 2139-2145, 1996.
134. Walisser JA, Bunger MK, Glover E, Harstad EB, and Bradfield CA. Patent ductus venosus and dioxin resistance in mice harboring a hypomorphic Arnt allele. J Biol Chem 279: 16326-16331, 2004.
135. Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, and Eckardt KU. Differentiating the functional role of hypoxia-inducible factor (HIF)-1α and HIF-2α (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2α target gene in Hep3B and Kelly cells. FASEB J 18: 1462-1464, 2004.
136. Wenger RH, Stiehl DP, and Camenisch G. Integration of oxygen signaling at the consensus HRE (Abstract). Sci STKE 2005: re12, 2005.
137. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, and Eckardt KU. Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs. FASEB J 17: 271-273, 2003.
138. Wykoff CC, Sotiriou C, Cockman ME, Ratcliffe PJ, Maxwell P, Liu E, and Harris AL. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 90: 1235-1243, 2004.
139. Yuan HT, Li XZ, Pitera JE, Long DA, and Woolf AS. Peritubular capillary loss after mouse acute nephrotoxicity correlates with downregulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1α. Am J Pathol 163: 2289-2301, 2003.
140. Yun Z, Maecker HL, Johnson RS, and Giaccia AJ. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell 2: 331-341, 2002.
141. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, and Maher ER. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62: 3803-3811, 2002.
142. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, and Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J 17: 5085-5094, 1998.
143. Zhang H, Akman HO, Smith EL, Zhao J, Murphy-Ullrich JE, and Batuman OA. Cellular response to hypoxia involves signaling via Smad proteins. Blood 101: 2253-2260, 2003.
144. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, and Semenza GL. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000.
145. Zimmer M, Doucette D, Siddiqui N, and Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2: 89-95, 2004.